Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Manufactures pharmaceuticals

Pentech Pharmaceuticals, Inc. is an American private company located in Rolling Meadows, IL. The firm engages in prescription drug therapies, delivery systems and applications. It was founded by Robert Fait.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Britannia Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products for the neurology market. It mainly develops products for the treatment of Parkinson��s disease. Its products include APO-go PEN intermittent subcutaneous injection, APO-go continuous infusion, Briotlofex, and Denzapine. The company was founded in 1982 and is headquartered in Reading, the United Kingdom.

Purdue Pharma L.P. is a privately held pharmaceutical company owned principally by descendants of Mortimer and Raymond Sackler. In 2007, it paid out one of the largest fines ever levied against a pharmaceutical firm for mislabeling its product OxyContin, and three executives were found guilty of criminal charges. Although the company shifted its focus to abuse-deterrent formulations, Purdue continued to market and sell opioids, and continued to be involved in lawsuits around the opioid epidemic in the United States. Purdue filed for Chapter 11 bankruptcy protection on September 15, 2019 in New York.

Sunovion Pharmaceuticals Inc. (formerly Sepracor) engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders, and other illnesses. Its products include LUNESTA medicine that helps people sleep better; XOPENEX levalbuterol HCl inhalation solution; and BROVANA aformoterol tartrate inhalation solution. The company's products also comprise OMNARIS ciclesonide nasal spray; ALVESCO ciclesonide HFA inhalation aerosol; and LATUDA, an oral antipsychotic tablet for the treatment of schizophrenia. It offers products for the treatment of depression, epilepsy, neuropathic pain, and insomnia, as well as respiratory conditions, such as asthma, allergic rhinitis, and chronic obstructive pulmonary diseases.

TAP Pharmaceutical Products was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. The company markets Prevacid and Lupron Depot, both leaders in their classes. Joint venture came to an end in March 2008 and Takeda took over the TAP. Lupron Depot is indicated for the palliative treatment of advanced prostate cancer, for management of endometriosis, in combination with iron for the preoperative treatment of anemia caused by uterine fibroids, and for the treatment of children with central precocious puberty.

C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Nippon Chemiphar Co., Ltd. engages in the healthcare business. It manufactures, sells, imports, and exports ethical pharmaceuticals and diagnostic agents. It operates through the Pharmaceuticals and Others segments. The Pharmaceuticals segment manufactures and sells prescription drugs. The Others segment includes safety testing consignment, healthcare, and real estate businesses. The company was founded by Akira Yamaguchi on June 16, 1950 and is headquartered in Tokyo, Japan.

Tasmanian Alkaloids is a fully-integrated manufacturer of controlled substances providing medicinal opiates from patented poppy varieties grown on the farms of Tasmania. The people of this enterprise, at the factory and on the farms, are committed to the highest quality standards and good manufacturing practice. They are committed to ensuring that our long-term business partners receive a fully reliable supply of our product.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Cenes Ltd., a subsidiary of PAION AG, is a company headquartered in Histon, UK. The firm develops treatments for diseases of the central nervous system.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics. Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief. Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects. Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.